Exhibit 10.5

    

     

    

    UNIT PURCHASE AGREEMENT

    

    

    THIS UNIT PURCHASE AGREEMENT (as it may from time to time be amended, this “Agreement”), dated as of [●], 2020, is entered into by and among HumanCo Acquisition Corp., a Delaware corporation (the “Company”), and CAVU Venture Partners III, LP, a Delaware limited partnership (the “Purchaser”).

    

    

    WHEREAS, the Company intends to
      consummate an initial public offering of the Company’s units (the “Public Offering”), each unit consisting of one share of Class A common stock of
      the Company, par value $0.0001 per share (each, a “Share”), and one-half of one redeemable warrant (each, a “Fractional Warrant”), each whole warrant entitling the holder to
      purchase one Share at an exercise price of $11.50 per Share, as set forth in the Company’s Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “SEC”), File Number 333-[●] (as amended, the “Registration Statement”), under the Securities Act of 1933,
      as amended (the “Securities Act”).

    

    

    WHEREAS, the Purchaser has agreed to
      purchase, at a price of $10.00 per unit, an aggregate of 2,500,000 units (the “CAVU Units”). Each CAVU Unit is identical to the units to be sold in
      the Public Offering, except as described in the Registration Statement.

    

    

    NOW THEREFORE, in consideration of
      the mutual promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows:

    

    

    AGREEMENT

    

    

    Section 1. Authorization, Purchase and
        Sale; Terms of the CAVU Units.

    

    

    A. Authorization of the CAVU Units.
      The Company has duly authorized the issuance and sale of the CAVU Units to the Purchaser.

    

    

    B. Purchase and Sale of the CAVU Units.

    

    

    On the date of the consummation of the Public Offering (the “IPO Closing Date”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, 2,500,000 CAVU Units at a price of $10.00 per unit for an aggregate purchase
      price of $25,000,000 (the “Purchase Price”). The Purchaser shall pay the Purchase Price by wire transfer of immediately available funds in
      accordance with the Company’s wiring instructions, at least one (1) business day prior to the IPO Closing Date. On the IPO Closing Date, upon the payment by the Purchaser of the Purchase Price, by wire transfer of immediately available funds to the
      Company, the Company, at its option, shall deliver a certificate evidencing the CAVU Units purchased on such date duly registered in the Purchaser’s name to the Purchaser or effect such delivery in book-entry form.

    C. Terms of the CAVU Units.

    

    

    (i) The Shares underlying the CAVU Units (the “CAVU Shares”) shall have the terms set forth in the Company’s Amended and Restated Certificate of Incorporation (the “Charter”)
      and shall be subject to the terms of a letter agreement to be entered into by the Company, the Purchaser and the other parties thereto, in connection with the Public Offering (the “Letter Agreement”).

    

    

    (ii) The Warrants underlying the CAVU Units (the “CAVU Warrants”) shall have the terms set forth in a Warrant Agreement to be entered into by the Company and a warrant agent, in connection with the Public Offering (the “Warrant Agreement”), and shall be subject to the terms of the Letter Agreement.

    

    

    (iii) At the time of, or prior to, the IPO Closing Date, the Company, the Purchaser and the other parties thereto shall
      enter into a registration and stockholder rights agreement (the “Registration and Stockholder Rights Agreement”) pursuant to which the Company will
      grant certain registration rights to the Purchaser relating to the CAVU Shares and CAVU Warrants.

    
      
        


    

    Section 2. Representations and Warranties
        of the Company.

    

    

    As a material inducement to the Purchaser to enter into this Agreement and to purchase the CAVU Units, the Company hereby represents and
      warrants to the Purchaser (which representations and warranties shall survive the IPO Closing Date) that:

    

    

    A. Incorporation and Corporate Power.
      The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and is qualified to do business in every jurisdiction in which the failure to so qualify would reasonably be expected to
      have a material adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated by this Agreement, the
      Charter and the Warrant Agreement.

    

    

    B. Authorization; No Breach.

    

    

    (i) The execution, delivery and performance of this Agreement and the CAVU Units have been duly authorized by the
      Company as of the IPO Closing Date. This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other
      laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law). Upon issuance in accordance with, and payment pursuant to, the terms of the Charter,
      the Warrant Agreement and this Agreement, the CAVU Units will constitute valid and binding obligations of the Company, enforceable in accordance with their terms as of the IPO Closing Date.

    

    

    (ii) The execution and delivery by the Company of this Agreement and the CAVU Units, the issuance and sale of the CAVU
      Units, the issuance of the CAVU Shares upon exercise of the CAVU Warrants and the fulfillment of and compliance with the respective terms hereof and thereof by the Company, do not and will not as of the IPO Closing Date (a) conflict with or result in
      a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien, security interest, charge or encumbrance upon the Company’s capital stock or assets under, (d) result in a violation of, or
      (e) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any court or administrative or governmental body or agency pursuant to the certificate of incorporation or the bylaws of the
      Company (in effect on the date hereof or as may be amended prior to completion of the Public Offering) or any material law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company
      is subject, except for any filings required after the date hereof under federal or state securities laws.

     

    

    C. Title to Securities. Upon
      issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, the CAVU Shares issuable upon exercise of the CAVU Warrants will be duly and validly issued, fully paid and nonassessable. Upon issuance in accordance
      with, and payment pursuant to, the terms hereof and the Warrant Agreement, the Purchaser will have good title to the CAVU Warrants purchased by it and the CAVU Shares issuable upon exercise of such CAVU Warrants, free and clear of all liens, claims
      and encumbrances of any kind, other than (i) transfer restrictions hereunder and under the other agreements contemplated hereby, (ii) transfer restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due
      to the actions of the Purchaser.

    

    

    D. Governmental Consents. No
      permit, consent, approval or authorization of, or declaration to or filing with, any governmental authority is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of
      any other transactions contemplated hereby.

    

    

    E. Regulation D Qualification.
      Neither the Company nor, to its actual knowledge, any of its affiliates, members, officers, directors or beneficial shareholders of 20% or more of its outstanding securities, has experienced a disqualifying event as enumerated pursuant to Rule 506(d)
      of Regulation D under the Securities Act.

    
      
        


    

    Section 3. Representations and Warranties
        of the Purchaser.

    

    

    As a material inducement to the Company to enter into this Agreement and to issue and sell the CAVU Units to the Purchaser, the Purchaser
      hereby represents and warrants to the Company (which representations and warranties shall survive the IPO Closing Date) that:

    

    

    A. Organization and Requisite Authority.
      The Purchaser possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.

    

    

    B. Authorization; No Breach.

    

    

    (i) This Agreement constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its
      terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in
      equity or law).

    

    

    (ii) The execution and delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms
      hereof by the Purchaser does not and shall not as of the IPO Closing Date (a) conflict with or result in a breach by the Purchaser of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation of any lien,
      security interest, charge or encumbrance upon the Purchaser’s equity or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing with, any
      court or administrative or governmental body or agency pursuant to the Purchaser’s organizational documents in effect on the date hereof or as may be amended prior to completion of the contemplated Public Offering, or any material law, statute, rule
      or regulation to which the Purchaser is subject, or any agreement, instrument, order, judgment or decree to which the Purchaser is subject, except for any filings required after the date hereof under federal or state securities laws.

    

    

    C. Investment Representations.

    

    

    (i) The Purchaser is acquiring the CAVU Units and, upon exercise of the CAVU Warrants, the CAVU Shares issuable upon
      such exercise (collectively, the “Securities”) for its own account, for investment purposes only and not with a view towards, or for resale in
      connection with, any public sale or distribution thereof.

    

    

    (ii) The Purchaser is an “accredited investor” as such term is defined in Rule 501(a)(3) of Regulation D, and the
      Purchaser has not experienced a disqualifying event as enumerated pursuant to Rule 506(d) of Regulation D under the Securities Act.

    

    

    (iii) The Purchaser understands that the Securities are being offered and will be sold to it in reliance on specific
      exemptions from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations and warranties of the
      Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities.

    

    

    (iv) The Purchaser did not decide to enter into this Agreement as a result of any general solicitation or general
      advertising within the meaning of Rule 502(c) under the Securities Act.

    

    

    (v) The Purchaser has been furnished with all materials relating to the business, finances and operations of the Company
      and materials relating to the offer and sale of the Securities which have been requested by the Purchaser. The Purchaser has been afforded the opportunity to ask questions of the executive officers and directors of the Company. The Purchaser
      understands that its investment in the Securities involves a high degree of risk and it has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the acquisition of the
      Securities.

    
      
        


    

    (vi) The Purchaser understands that no United States federal or state agency or any other government or governmental
      agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the
      Securities.

    

    

    (vii) The Purchaser understands that: (a) the Securities have not been and are not being registered under the Securities
      Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in reliance on an exemption therefrom; and (b) except as specifically set forth in the
      Registration and Stockholder Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of any
      exemption thereunder. In this regard, the Purchaser understands that the SEC has taken the position that promoters or affiliates of a blank check company and their transferees, both before and after an initial business combination, are deemed to be
      “underwriters” under the Securities Act when reselling the securities of a blank check company. Based on that position, Rule 144 adopted pursuant to the Securities Act would not be available for resale transactions of the Securities despite technical
      compliance with the requirements of such Rule, and the Securities can be resold only through a registered offering or in reliance upon another exemption from the registration requirements of the Securities Act.

    

    

    (viii) The Purchaser has such knowledge and experience in financial and business matters, knowledge of the high degree
      of risk associated with investments in the securities of companies in the development stage such as the Company, is capable of evaluating the merits and risks of an investment in the Securities and is able to bear the economic risk of an investment
      in the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial needs and contingencies and will have no current or anticipated future needs for
      liquidity which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investments in the Securities.

    

    

    D. No Conflicts. The execution, delivery and
      performance of this Agreement and the consummation by Purchaser of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) Purchaser’s charter documents, (ii) any agreement or instrument to which
      Subscriber is a party or (iii) any law, statute, rule or regulation to which Purchaser is subject, or any agreement, order, judgment or decree to which Purchaser is subject.

    

    

    E. No Legal Advice from Company. Purchaser
      acknowledges it has had the opportunity to review this Agreement and the transactions contemplated by this Agreement and the other agreements entered into between the parties hereto with Purchaser’s own legal counsel and investment and tax advisors. 
      Except for any statements or representations of the Company made in this Agreement and the other agreements entered into between the parties hereto, Purchaser is relying solely on such counsel and advisors and not on any statements or representations
      of the Company or any of its representatives or agents for legal, tax or investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws of any jurisdiction.

     

      

    Section 4. Conditions of the Purchaser’s
        Obligations.

    

    

    The obligations of the Purchaser to purchase and pay for the CAVU Units are subject to the fulfillment, on or before the IPO Closing Date,
      of each of the following conditions:

    

    

    A. Representations and Warranties.
      The representations and warranties of the Company contained in Section 2 shall be true and correct at and as of the IPO Closing Date as though then made.

    
      
        


    

    B. Performance. The Company
      shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the IPO Closing Date.

    

    

    C. No Injunction. No
      litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
      having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement, the Charter or the Warrant Agreement.

    

    

    D. Charter, Warrant Agreement and
          Registration and Stockholder Rights Agreement. The Company shall have entered into the Charter, the Warrant Agreement and the Registration and Stockholder Rights Agreement, in each case on terms satisfactory to the Purchaser.

    

    

    Section 5. Conditions of the Company’s
        Obligations.

    

    

    The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before the IPO Closing Date, of
      each of the following conditions:

    

    

    A. Representations and Warranties.
      The representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and as of the IPO Closing Date as though then made.

    

    

    B. Performance. The
      Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before the IPO Closing Date.

    

    

    C. Corporate Consents. The
      Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery and performance of this Agreement, the Charter and the Warrant Agreement and the issuance and sale of the CAVU Units hereunder.

    

    

    D. No Injunction. No
      litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization
      having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement, the Charter or the Warrant Agreement.

    

    

    E. Charter, Warrant Agreement and
          Registration and Stockholder Rights Agreement. The Company shall have entered into the Charter, the Warrant Agreement and the Registration and Stockholder Rights Agreement, in each case on terms satisfactory to the Company.

    

    

    Section 6. Termination.

    

    

    This Agreement may be terminated by the Company or the Purchaser at any time after [March 31], 2021 upon written notice to the other party
      hereto if the closing of the Public Offering does not occur prior to such date.

    

    

    Section 7. Survival of Representations and
        Warranties.

    

    

    All of the representations and warranties contained herein shall survive the IPO Closing Date.

    

    

    Section 8. Definitions.

    

    

    Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms in the Registration Statement.

    
      
        


    

    Section 9. Miscellaneous.

    

    

    A. Successors and Assigns.
      Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so
      expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement, other than assignments by the Purchaser to affiliates thereof (including, without limitation one or more of its members).

    

    

    B. Severability. Whenever
      possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall
      be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

    

    

    C. Counterparts. This
      Agreement may be executed simultaneously in two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement. A signed copy of this
      Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

    

    

    D. Descriptive Headings; Interpretation.
      The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of example rather than by limitation.

    

    

    E. Governing Law. This
      Agreement shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with the internal laws of the State of New York, without giving effect to conflicts of law principles that
      would result in the application of the laws of another jurisdiction.

    

    

    F. Amendments. This
      Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto.

    

    

    [Signature page follows]

    
      
        


    

    

    

    IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first set forth above.

    

    

    	 	
            COMPANY:

          
	 	 	 
	 	
            HUMANCO ACQUISITION CORP.

          
	 	 
	 	
            By:

          	 
	 	
            Name:

          	 
	 	
            Title:

          	 
	 	 	 
	 	
            PURCHASER:

          
	 	 
	 	
            CAVU VENTURE PARTNERS III, LP

          
	 	 
	 	
            By:

          	 
	 	
            Name:

          	 
	 	
            Title:

          	 


    

    

    
      [Signature Page to CAVU Units Purchase Agreement]